The Canadian Maraviroc RCT To Augment Rehabilitation Outcomes After Stroke
Status:
Not yet recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
The CAMAROS trial is a randomized controlled phase II trial analyzing the effect of coupling
a C-C chemokine receptor 5 (CCR5) antagonist, Maraviroc (Celsentri), and exercise to improve
both upper and lower extremity recovery after a stroke.
Phase:
Phase 2
Details
Lead Sponsor:
University of Calgary
Collaborators:
Dalhousie University Memorial University of Newfoundland Parkwood Hospital, London, Ontario Riverview Health Centre Foundation Sunnybrook Health Sciences Centre The Dr. Miriam and Sheldon G. Adelson Medical Research Foundation University Health Network, Toronto University of British Columbia University of California, Los Angeles